Indication
Treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
Medicine details
- Medicine name:
- pegcetacoplan (Aspaveli)
- SMC ID:
- SMC2928
- Pharmaceutical company
- Swedish Orphan Biovitrum
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC